Opinion divided at Boots over statin switch
A survey of Boots pharmacists has revealed mixed opinions about the potential reclassification of simvastatin as a pharmacy medicine.
The survey, carried out by the Boots Pharmacists Association, indicated
an equal split between those in favour of and those against the reclassification.
An opinion that summed up the responses was: “I think it is difficult
to simplify the argument as for and against reclassification. In my opinion,
the proposed reclassification has too many holes in it, including absence
of monitoring, lack of coherent follow-up and poor supporting evidence
for the use of simvastatin at this dose.
“However, I am not opposed to the reclassification of simvastatin
per se. I entirely agree that pharmacists need to embrace the reclassification
but we must ensure that it is on our terms.”
Some of the points raised in support of the switch include the fact that
it could be the start of chronic disease management in the community,
that patients will have better access to a proven medicine and that it
is a chance for pharmacists to extend their role.
Several pharmacists suggested simvastatin should be sold under a protocol
or only by pharmacists. Those against the move highlighted safety, and
a lack of testing and monitoring as particular concerns. “Will
the price of the product also take into account the level of counselling
required to be given by the pharmacist,” asked one respondent. |
The
Pharmaceutical Journal